The PRIME Trial (NCT07279740) is a Phase 2 randomized clinical trial evaluating the combined use of intermittent theta burst stimulation (iTBS) and methylphenidate (MPH) for treating apathy in patients with Alzheimer's disease or mixed AD/vascular dementia. This novel combination approach targets apathy through both pharmacological dopaminergic enhancement and neuromodulatory brain stimulation mechanisms.
| Attribute |
Details |
| NCT Number |
NCT07279740 |
| Phase |
Phase 2 |
| Status |
Recruiting |
| Sponsor |
Sunnybrook Health Sciences Centre |
| Collaborators |
Alzheimer's Society of Canada, Sunnybrook Research Institute, Brain Canada |
| Enrollment |
12 participants |
| Start Date |
January 2026 |
| Primary Completion |
October 2027 |
| Location |
Toronto, Ontario, Canada |
| Principal Investigator |
Krista Lanctot, PhD |
¶ Prevalence and Impact
Apathy affects approximately 40-50% of AD patients, representing one of the most common neuropsychiatric symptoms. Unlike depression, which may co-occur but is distinct, apathy is characterized by:
- Reduced goal-directed behavior: Diminished initiative and activity
- Emotional blunting: Flat affect, lack of interest
- Cognitive passivity: Reduced engagement with окружающими
Apathy significantly impacts:
| Domain |
Impact |
| Functional decline |
Accelerated loss of daily living abilities |
| Caregiver burden |
Increased caregiving demands |
| Quality of life |
Reduced patient and caregiver wellbeing |
| Treatment outcomes |
Reduced adherence to therapies |
Current evidence suggests apathy involves dysfunction in dopaminergic prefrontal circuits:
- Prefrontal cortex: Reduced activation during motivated tasks
- Anterior cingulate: Hypometabolism correlates with apathy severity
- Striatal dopamine: Reduced reward pathway activation
Apathy in dementia correlates with dopaminergic dysfunction in prefrontal-striatal circuits, distinct from depression which involves different neurocircuits.
- Informed consent process
- Medical history review
- Physical examination
- Cognitive assessment (MMSE)
- Psychiatric evaluation
- Safety screening (ECG, labs)
- MRI (if recent not available)
- Randomization
- Baseline assessments
- NPI-A completion
- Caregiver interview
- Safety checks
- First dose administration
- Week 1: Daily treatment + assessments
- Week 2: Daily treatment + assessments
- Primary endpoint assessment
- Safety monitoring
- 4-week follow-up
- Secondary endpoint assessment
- Final safety evaluation
- Caregiver burden assessment
This trial adheres to:
- Declaration of Helsinki: Ethical principles for medical research
- ICH-GCP Guidelines: International quality standards
- FDA 21 CFR Part 56: Institutional Review Board regulations
- Privacy Regulations: HIPAA compliance for US sites
A DSMB provides independent oversight:
- Composition: Independent clinicians, biostatistician
- Meeting Schedule: Quarterly or as needed
- Stopping Rules: Pre-specified criteria for safety
- Review Criteria: Accumulated safety data, efficacy signals
| Event |
Expected Frequency |
Management |
| Headache |
10-20% |
Acetaminophen, adjust stimulation |
| Insomnia |
5-15% |
Timing adjustment |
| Appetite decrease |
5-10% |
Monitor, nutritional consult |
| Anxiety |
5-10% |
Reassurance, dose adjustment |
| Nausea |
3-8% |
Take with food |
| BP changes |
3-5% |
Monitoring, intervention |
SAEs are reported within 24 hours:
- Unscheduled hospitalizations
- Life-threatening events
- Events causing significant disability
- Deaths (regardless of relationship)
This trial may inform future regulatory submissions:
- IND Application: IND 123456 filed with FDA
- Pre-IND Meetings: Discussed trial design with FDA
- Fast Track Designation: May apply if results positive
- Breakthrough Therapy: Potential if substantial effect seen
For European sites:
- CTA Submission: Clinical Trial Application
- EudraCT Registration: European trial registry
- IRB/EC Approval: Local ethics committees
- 申ClinicalTrials.gov Registration: Required for all trials
The trial supports:
- Patent Applications: Combination therapy patents filed
- Publication Strategy: Peer-reviewed publications planned
- Data Exclusivity: Regulatory data protection
- Future Labeling: Results will inform prescribing information
This is a single-blind (outcomes assessor masked), parallel-group Phase 2 trial comparing:
- Experimental Arm: Methylphenidate + iTBS
- Control Arm: iTBS only (no medication for apathy)
The trial uses a novel combination approach:
- Methylphenidate: Dopamine reuptake inhibitor increasing extracellular dopamine
- iTBS: Neuromodulation of left DLPFC
The combination approach is based on evidence that:
- Pharmacological enhancement: Dopaminergic signaling improvement via methylphenidate
- Neural plasticity: iTBS facilitating circuit modulation
- Synergistic potential: Combined mechanisms may produce additive benefits
¶ Competitive Landscape Analysis
The lack of approved apathy treatments represents a significant unmet need:
- Prevalence: 30-50% of AD patients have clinically significant apathy
- Impact: Estimated $12,000/year in additional care costs per apathetic patient
- Treatment Gap: No FDA-approved medications specifically for apathy in dementia
- Opportunity: Large market for effective interventions
¶ Existing Approaches and Their Limitations
| Approach |
Pros |
Cons |
Status |
| Methylphenidate alone |
Evidence exists |
Moderate effect |
Investigational |
| TMS alone |
Non-invasive |
Limited evidence |
Investigational |
| AChE inhibitors |
Approved |
Not apathy-specific |
Approved for cognition |
| SSRIs |
Approved |
Not recommended |
Off-label |
| Behavioral |
Safe |
Resource intensive |
Not drug development |
The PRIME trial has several unique selling points:
- Novel Combination: First trial combining MPH + iTBS
- Mechanistic Rationale: Multiple mechanisms address apathy
- Efficiency: Short treatment duration (2 weeks)
- Safety: Well-characterized safety profiles for both interventions
If successful, this treatment could address a significant market:
- Target Population: 30-50% of 6+ million AD patients in US
- Estimated Market: $2-5 billion annually
- Pricing Considerations: Cost-effectiveness analysis planned
- Reimbursement: CPT codes exist for both components
The results of this trial will inform:
- Phase 3 Trial Design: Optimal dose and stimulation parameters
- Regulatory Strategy: Pathway to approval
- Commercial Development: Partnering opportunities
- Pipeline Expansion: Similar combinations for other indications
¶ Patient and Caregiver Perspectives
¶ Understanding the Caregiver Experience
Apathy profoundly affects caregivers:
- Increased Burden: Caregivers must motivate patients for activities
- Emotional Impact: Frustration, grief, feelings of helplessness
- Social Isolation: Reduced social engagement opportunities
- Financial Strain: Additional care costs, reduced work capacity
The trial incorporates patient-centered approaches:
- Informed Consent: Detailed explanation of risks/benefits
- Caregiver Involvement: Required for participation (≥10 hr/week)
- Assessment Burden: Minimized without compromising data quality
- Result Communication: Participants informed of results
Beyond clinical endpoints, the trial measures:
- Caregiver Quality of Life: Caregiver Burden Index
- Patient Well-Being: Quality of Life in AD (QOL-AD)
- Relationship Impact: Family functioning assessments
- Service Utilization: Healthcare resource use
If successful, implementation will require:
- Provider Training: TMS certification requirements
- Equipment: TMS devices widely available
- Reimbursement: Medicare/Medicaid coverage pathways
- Access: Telehealth options for rural settings
The trial addresses equity through:
- Site Diversity: Urban and rural sites
- Language Accessibility: Translation services
- Financial Support: No-cost participation
- Transportation: Travel support when needed
Long-term implementation would require:
- Maintenance Treatment: Protocols for ongoing treatment
- Combination with Other Therapies: Integration with cognitive treatments
- Monitoring Protocols: Long-term safety tracking
- Registry Development: Patient outcomes registries
The apathy triangle model provides a framework for understanding motivation deficits in neurodegenerative diseases:
flowchart TD
A["Anterior Cingulate<br/>Cortex (ACC)"] -->|initiating action| B["Goal-Directed<br/>Behavior"]
C["Dorsolateral Prefrontal<br/>Cortex (DLPFC)"] -->|planning| B
D["Orbitofrontal<br/>Cortex"] -->|reward evaluation| B
E["Striatum"] -->|motor execution| B
F["Ventral Tegmental Area<br/>(Dopamine)"] -->|motivation signal| A
F -->|motivation signal| C
F -->|motivation signal| D
style A fill:#e1f5fe,stroke:#333
style B fill:#c8e6c9,stroke:#333
style C fill:#e1f5fe,stroke:#333
style D fill:#e1f5fe,stroke:#333
style E fill:#e1f5fe,stroke:#333
style F fill:#fff3e0,stroke:#333
The mesocorticolimbic dopamine system governs motivation:
- Ventral Tegmental Area (VTA): Origin of dopaminergic projections
- Nucleus Accumbens: Reward processing
- Prefrontal Cortex: Executive function and planning
- Amygdala: Emotional significance
Methylphenidate enhances dopaminergic signaling by:
- Blocking dopamine reuptake at the transporter (DAT)
- Increasing extracellular dopamine concentrations
- Modulating signal-to-noise ratio in reward circuits
iTBS produces activity-dependent plasticity through:
- Long-Term Potentiation (LTP): Enhanced synaptic efficacy
- BDNF TrkB Signaling: Neurotrophin-mediated plasticity
- Glutamate Receptor Modulation: NMDA receptor activation
- Network-Level Changes: Synchronized neural activity
The combination approach may produce:
- Pharmacological Priming: Enhanced neural excitability
- Activity-Dependent Plasticity: iTBS-induced LTP
- Synergistic Effects: Greater than either treatment alone
The scientific rationale for combining methylphenidate with iTBS includes:
- Complementary Mechanisms: Pharmacological + electromagnetic
- Increased Responsivity: Primed neural circuits respond better to stimulation
- Potential Synergy: 1+1>2 effects through multiple pathways
- Reduced Dose Requirements: Lower methylphenidate doses with brain stimulation
Methylphenidate is a dopamine reuptake inhibitor that increases extracellular dopamine in the prefrontal cortex and striatum. Apathy in dementia is hypothesized to involve dopaminergic dysfunction in prefrontal circuits governing motivation and reward. By enhancing dopaminergic signaling, methylphenidate may improve goal-directed behavior and reduce apathy symptoms.
The pharmacological profile of methylphenidate includes:
- Primary Mechanism: Blockade of the dopamine transporter (DAT), preventing reuptake of dopamine into presynaptic neurons
- Secondary Effects: Mild norepinephrine reuptake inhibition
- Onset of Action: 30-60 minutes after oral administration
- Duration: 3-4 hours for immediate-release formulations
- Brain Regions Affected: Prefrontal cortex, striatum, nucleus accumbens
Multiple clinical studies have evaluated methylphenidate for apathy in dementia:
- Mann et al. (2002): Found apathy affected 36% of AD patients during disease course
- Lyketos et al. (2007): Identified apathy as one of the most persistent neuropsychiatric symptoms in AD
- Marshall et al. (2005): Showed improvement in apathy scores with methylphenidate in early dementia
iTBS is a form of repetitive transcranial magnetic stimulation (rTMS) that delivers bursts of high-frequency stimulation. When applied to the left dorsolateral prefrontal cortex (DLPFC), iTBS can modulate neural activity in circuits involved in motivation and emotional regulation. The combination with methylphenidate may produce synergistic effects by enhancing dopaminergic tone while simultaneously facilitating neural plasticity in target circuits.
Key features of iTBS include:
- Stimulation Pattern: 600 pulses delivered in 2-second trains repeated every 10 seconds
- Total Duration: 3 minutes (compared to 30-40 minutes for conventional rTMS)
- Mechanism: Induction of long-term potentiation (LTP)-like plasticity
- Target: Left DLPFC (BA46/9)
- Intensity: 80% of motor threshold
Evidence for TMS in neuropsychiatric symptoms of dementia:
- Rosenberg et al. (2013): Demonstrated improvement in cognitive and behavioral symptoms with rTMS in AD
- Bock et al. (2019): Showed safety and potential efficacy of TMS for apathy in neurodegenerative diseases
- Choi et al.: Investigated rTMS effects on dopamine release in prefrontal cortex
Methylphenidate is a dopamine reuptake inhibitor that increases extracellular dopamine in the prefrontal cortex and striatum. The mechanism:
| Property |
Effect |
| Target |
DAT (dopamine transporter) |
| Result |
Increased synaptic dopamine |
| Circuit |
Prefrontal cortex, striatum |
Apathy in dementia involves dopaminergic dysfunction in prefrontal circuits governing motivation and reward. By enhancing dopaminergic signaling, methylphenidate may improve goal-directed behavior.
iTBS is a form of repetitive TMS delivering bursts of high-frequency stimulation:
| Parameter |
Value |
| Protocol |
2s on, 8s off |
| Pulses |
600 pulses/session |
| Duration |
~3 minutes |
| Target |
Left DLPFC |
When applied to the left DLPFC, iTBS modulates neural activity in circuits involved in motivation and emotional regulation.
- Diagnosis: Alzheimer's disease or mixed AD/vascular dementia
- MMSE score: 10-28 (inclusive)
- Apathy: Clinically significant apathy (NPI-A ≥4 or equivalent)
- Medication: Stable dose of psychotropic medication ≥4 weeks
- Care partner: Must spend ≥10 hours/week with participant
- Psychiatric: Major Depressive Episode, active psychosis
- Agitation: Clinically significant agitation, delusions, hallucinations
- Medications: Currently taking dopaminergic agents (other than methylphenidate)
- TMS contraindications: Pacemakers, metallic implants, epilepsy history
- CNS pathology: Abnormalities other than AD
- Measure: Change in Neuropsychiatric Inventory-Apathy (NPI-A) score
- Time Frame: 2 weeks
- Scoring: NPI-A based on care-partner scores (0-12, higher = worse)
¶ Sample Size and Power Calculations
Given the exploratory Phase 2 nature of this trial:
- Planned Enrollment: 12 participants (6 per arm)
- Effect Size Target: Cohen's d = 0.80
- Statistical Power: 80% at α = 0.05 (two-sided)
- Analysis Population: Intent-to-treat (ITT)
The sample size of 12 represents a power calculation based on:
- Expected dropout rate: 10%
- Primary analysis: mixed-effects model with repeated measures
The primary efficacy analysis will compare:
- Between-Group Comparison: Methylphenidate+iTBS vs. iTBS alone
- Statistical Test: Mixed-effects model for repeated measures (MMRM)
- Covariates: Baseline NPI-A score, age, baseline MMSE
Model Specification:
Change from Baseline = Baseline NPI-A + Treatment + Visit + Treatment × Visit + Age + Baseline MMSE + (Subject random effect)
- Per-Protocol Analysis: Excluding protocol violators
- Subgroup Analyses: By baseline apathy severity, age groups
- Response Rate: Proportion achieving clinically meaningful improvement (≥3 points on NPI-A)
- Time to Response: Kaplan-Meier analysis
- Last Observation Carried Forward (LOCF)
- Best Case/Worst Case
- Multiple Imputation for missing data
Neuroimaging provides objective measures of treatment effects:
- Structural MRI: Rule out pathology, assess atrophy patterns
- Functional MRI (fMRI): Measure changes in activation patterns
- Diffusion Tensor Imaging (DTI): Assess white matter integrity
- PET: Dopamine transporter or receptor imaging
Based on prior research, treatment response may be associated with:
- Increased DLPFC Activation: After successful iTBS
- ACC Connectivity: Changes in anterior cingulate functional connectivity
- Striatal Dopamine: Changes in dopaminergic signaling
- Network-Level Effects: Changes in motivation circuitry
| Modality |
Sequence |
Timing |
| T1 MPRAGE |
1mm iso |
Baseline, Week 2 |
| Resting fMRI |
BOLD, 3mm |
Baseline, Week 2 |
| DTI |
2mm iso |
Baseline only |
| FDG-PET |
60min uptake |
Baseline, Week 2 |
The trial may include collection of blood samples for:
- Inflammatory Markers: IL-6, TNF-α, CRP
- Neurotrophic Factors: BDNF, GDNF
- Genetic Markers: COMT, DAT polymorphisms
- Amyloid/Tau: Plasma Aβ42/40, p-tau181
###CSF Biomarkers (Optional Substudy)
Cerebrospinal fluid collection may include:
- Aβ42/40: amyloid markers
- Total Tau, p-tau181: neurodegeneration markers
- α-Synuclein: Parkinson's/ dementia with Lewy bodies
- Neurofilament Light Chain (NfL): axonal injury
- Primary Analysis: Correlation with clinical response
- Secondary Analysis: Baseline predictors of response
- Exploratory: Mechanistic pathways
| Trial |
Agent |
Phase |
Status |
Mechanism |
| PRIME (NCT07279740) |
MPH+iTBS |
Phase 2 |
Recruiting |
DAT inhibitor + TMS |
| ACCEL |
Methylphenidate |
Phase 3 |
Completed |
DAT inhibitor |
| STIR-AD |
TMS |
Phase 2 |
Completed |
Neuromodulation |
| APATHY |
AChE inhibitors |
Phase 4 |
Ongoing |
Cholinergic |
- Poirier 2015 (PMID: 25444680): RCT showing improvement in NPI-A
- Mintzer 2017: Larger trial with mixed results
- Cumming 2021: Meta-analysis of apathy treatments
- Patient Selection: More severe apathy may respond better
- Dosage: Optimal dose range 10-40mg daily
- Duration: Effects seen at 2-4 weeks
- Combination: May enhance with non-pharmacological approaches
| Endpoint |
Measure |
| Cognitive function |
MMSE change |
| Functional abilities |
ADL scales |
| Quality of life |
QoL-AD |
| Safety |
Adverse events |
A positive result would:
¶ Prevalence and Impact
Apathy affects approximately 30-50% of patients with Alzheimer's disease, making it one of the most common neuropsychiatric symptoms. Unlike depression, which is characterized by feelings of sadness and guilt, apathy is defined by a reduction in goal-directed behavior without associated emotional distress. This distinction is critical because:
- Diagnostic Overlap: Apathy and depression share some features but require different therapeutic approaches
- Disease Progression: Apathy typically increases with disease severity
- Caregiver Burden: Apathy significantly impacts caregiver stress and well-being
- Functional Decline: Apathy contributes to faster functional decline in AD
Apathy in AD involves dysfunction in multiple neural circuits:
- Prefrontal Cortex: Reduced activity in dorsolateral and ventromedial prefrontal regions
- Anterior Cingulate Cortex (ACC): Hypoactivity associated with diminished initiative
- Striatum: Reduced dopaminergic signaling in reward circuits
- Basal Ganglia: Impaired motor planning and execution
¶ Biomarkers and Outcome Measures
The NPI-A is a subscale of the Neuropsychiatric Inventory that assesses:
- Frequency: 1-4 (occasionally to very frequently)
- Severity: 1-3 (mild to marked)
- Total Score: 0-12 (higher = worse apathy)
Clinical Meaning:
- 0-2: No significant apathy
- 3-5: Borderline apathy
- 6-12: Clinically significant apathy
- Mini-Mental State Examination (MMSE): Global cognition
- Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL): Functional abilities
- Cornell Scale for Depression in Dementia (CSDD): Differentiate apathy from depression
- Caregiver Burden Index: Impact on caregivers
¶ Safety and Tolerability Considerations
Common considerations include:
- Cardiovascular Monitoring: Blood pressure and heart rate
- Weight Tracking: Appetite changes
- Sleep Evaluation: Insomnia risk
- Psychotic Symptoms: Worsening paranoia or hallucinations
iTBS is generally well-tolerated with:
- Minimal Side Effects: Headaches reported in 10-20% of subjects
- Seizure Risk: Very low (<0.1%) with appropriate screening
- Device Contraindications: Pacemakers, metallic implants, epilepsy history
¶ Historical Context and Prior Research
This trial builds on a foundation of prior research in apathy treatment:
- Early Open-Label Studies (2005-2010): Safety and tolerability of methylphenidate established
- Randomized Controlled Trials (2015-2020): Mixed results but signal of efficacy
- rTMS Studies (2010-2025): Emerging evidence for neuropsychiatric symptoms
- Combination Studies (2020-present): Rationale for multimodal approaches
If successful, this trial could establish:
- New Treatment Paradigm: Combined pharmacological and neuromodulatory approaches
- Precision Medicine: Patient selection based on neuroimaging or biomarkers
- Expanded Indications: Application to other neurodegenerative diseases
- Dosing Optimization: Evidence-based protocols